In the above-stated abstract, the authors regret that the first author, Dewi Gathmyr, was not included.
The authors would like to apologize for any inconvenience caused.
POS-014 THE RELATIONSHIP BETWEEN IL-6, IL-10, TNF-α WITH AKI IN MODERATE AND SEVERE COVID-19 PATIENTS.
Introduction: Acute Kidney Injury is an important complication and is associated with increased mortality in COVID-19 due to inflammation and immune dysregulation, both at the beginning and during treatment. Aim: To determine the relationship between IL-6, IL-10, TNF-α with serum creatinine changes and their ability to predict incidence of AKI.
Methods: A prospective cohort study involving 43 moderate-to-severe COVID-19 patients in Pertamina Central Hospital Jakarta, Indonesia. This study was conducted between November 2020 to January 2021. We analyzed the changes in the data taken on the first and seventh day of treatment, or earlier if the patient died or was discharged. AKI is determined when changes in serum creatinine and urine output meet the criteria in the Kidney Disease: Improving Global Outcomes guidelines. The correlation between increase of cytokines and changes creatinine was analyzed. Receiver Operator Characteristic test was then performed to see the predictive ability of IL-6, IL-10, TNF-α on the incidence of AKI with minimal area under curve 0,7 with confidence interval 95% and p value <0.05.
Results: Changes in serum creatinine were only correlated with changes in serum IL-10 levels (r= -0.343; p 0.024). Serum TNF- levels on the first day of treatment were able to predict AKI on the seventh day (AUC 85%; p=0.045; 95%CI 0.737-0.963).
Conclusions: Changes in IL-10 is correlated with changes in serum creatinine. TNF-α on the first day of treatment can predict the incidence of AKI on the seventh day of treatment for moderate and severe COVID-19 patients.
No conflict of interest.